Enzolytics Inc (ENZC)

[foxi]

These are actually valuable points and the type of DD I encouraged you to share. So ima do a 180 and unblock ya.

But there's no good reason for you to use inflammatory and condescending language. It's dramatic and distracts everyone from the points you're trying to make.


From these filings:
https://www.otcmarkets.com/otcapi/company/financial-report/300160/content
https://www.otcmarkets.com/otcapi/company/financial-report/297979/content

ENZC lists the following as subsidiaries, affiliates and parent companies:
- Bioclonetics
- Biogenysis
- Virogentics
- ENZC SUB
- IMMB BG (49% owner)
- IMPL (50% owner? The OTC filings contradict by omission)
- Danhson Inc (contracted to produce the initial quantities of ITV-1 to be used for preclinical and clinical trial purposes)

There's one company not so clearly identified, but the description might match Rosetta:

On May 12, 2021, the Company granted a distributorship license to a European pharma entity giving it the right to distribute the Company's anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia. The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity has invested $2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company $3 Million in cash plus a 50% ownership in the Licensing Entity. This agreement will result in establishing a committed partner for sale and distribution of the Company's ITV-1 therapeutic in the Licensed Territory as well as 50% ownership in Licensee and its profit derived from sales in the Licensed Territory.

According to https://www3.wipo.int/madrid/monitor/en/showData.jsp?ID=ROM.1609000 which is for the Active (not pending!) EnzoImmune Active trademark:

832 Designation(s) under the Madrid Protocol
AL - AM - AU - AZ - BA - BR - BY - CA - CH - CN - CO - CU - CY - DZ - EG - FI - GE - ID - IL - IN - IR - IS - JP - KE - KG - KP - KR - KZ - LR - MA - MC - MD - ME - MK - MN - MX - MY - MZ - NO - NZ - OA - OM - PH - PK - RS - RU - RW - SD - SG - SY - TH - TJ - TM - TN - TR - UA - US - UZ - VN - ZM - ZW

527 Indications regarding use requirements
IN - MY - MZ - NZ - SG - US

It's weird to me that Chandra would tweet that "An ENZC Immunomodulator will be available soon in the US market." when Rosetta isn't listed by name as an affiliate in OTC filings, Rosetta is the one filing the trademark papers, Rosetta hasn't been named in ENZC official PR (afaik, and I'm going by memory here), and the USPTO's trademarking timeline isn't what most people would call "soon" (the standard timeline runs up to 18 months after initial filing)

But if there's already an active, approved trademark for Enzoimmune Active out of the EU, maybe that's all Rosetta needs to distribute the product in the USA, as an European import perhaps...

And if the "European pharma entity" in ENZC's filings relates to Rosetta, ENZC would receive $3 Million in cash plus a 50% ownership in the Licensing Entity as the initial deal, Rosetta would own $2 Million of ENZC Company Preferred Series E shares, and ENZC would be entitled to 50% of all future revenues from Rosetta products containing ITV-1 sold in whatever places the "Licensed Territory" entails.